# Medication history analysis

## You (2025-11-17T20:23:14.959000+00:00)

### **üß≠ Goal**

Analyze and evaluate the longitudinal psychiatric medication history of Suparna Goyal, with the objective of determining:

1. Which medications have demonstrably worked or failed, and why.
2. The underlying pharmacological or diagnostic reasons behind the persistent tremors (EPS, TD, or otherwise).
3. The mechanism of action and clinical rationale of each medication used‚Äîboth successful and unsuccessful.
4. The psychological, behavioral, and motor impact of each treatment phase.
5. An optimal, evidence-supported recommendation for a medication regimen, based on the historical evidence and best psychiatric practices for treatment-resistant schizophrenia with severe delusional dietary control and poor adherence.

---

### **üì¶ Return Format**

* **Section 1: Chronological Efficacy Matrix**
  Table summarizing each treatment phase with:

  * Date range
  * Medication(s) & dosages
  * Observed benefits
  * Observed side-effects
  * Notable behavioral changes
  * Adherence status

* **Section 2: Medication Mechanism Overview**
  For each drug (e.g. Olanzapine, Risperidone, Paliperidone, Aripiprazole, Pacitane, Betacap, Nexito):

  * Drug class
  * Mechanism of action
  * Primary therapeutic role in schizophrenia or related conditions
  * Common side-effects, especially extrapyramidal symptoms
  * Pharmacodynamic or pharmacokinetic interactions with other drugs used
  * Citations or references to relevant medical literature (e.g., NIH, PubMed, WHO, peer-reviewed psychiatric journals)

* **Section 3: Root Cause Analysis of Tremors**

  * Timeline of tremor onset vs medication changes
  * Evaluate likelihood of **acute vs tardive extrapyramidal symptoms**
  * Clinical interpretation of Pacitane and Betacap effectiveness
  * Potential irreversible neuroleptic-induced changes
  * Judgment on which drug(s) most likely contributed to or worsened the tremors, supported by mechanism and research

* **Section 4: Ethical & Treatment Context Review**

  * Note family‚Äôs documented concern about **Dr. Jyothirmayi**, including suspected conflict of interest with a specific clinic
  * Evaluate any patterns of **careless dose reductions** or **inadequate monitoring of motor side effects**
  * Caution against over-reliance on providers with known trust violations

* **Section 5: Treatment Recommendation Plan**

  * Clear, layered recommendation:

    * **Primary regimen** ‚Äì based on best clinical evidence and this patient‚Äôs history
    * **Contingency/backup options** ‚Äì in case of side-effects or poor response
  * If appropriate, recommend long-acting vs short-acting options
  * Include realistic management strategies for adherence, given patient‚Äôs history of deception and resistance
  * List **any labs, monitoring, or assessments** that should accompany the plan (e.g., AIMS scale for TD, thyroid tests)

---

### **‚ö†Ô∏è Warnings & Guardrails**

* Avoid assumptions unsupported by the clinical history provided.
* Clearly **distinguish speculation from evidence** (e.g., hallucinations have *not* been reported‚Äîdon‚Äôt overweigh antipsychotics for that symptom).
* Maintain neutrality regarding psychiatrist intentions‚Äîreport observed patterns, not motives.
* Do not prescribe‚Äîthis is a clinical reasoning task for educational or preparatory purposes only.
* Patient has historically demonstrated extreme control behaviors, dietary delusions, and poor insight‚Äîmedication effectiveness should be judged **behaviorally and relationally**, not just via internal symptom reports.

---

### **üìö Context & Additional Elements**

* Patient: Suparna Goyal
* Diagnosis: Schizophrenia (no hallucinations, prominent paranoia, dietary delusions, intermittent aggression)
* History of extreme **isolation, fasting, controlling behaviors**, and **involuntary physical symptoms (tremors)**.
* Timeline of all medications, behaviors, and regressions is documented in detail.
* Family has taken over care coordination and is seeking an evidence-based synthesis and treatment optimization.
* You are a **psychiatrist** interpreting this history with the lens of psychopharmacology, patient safety, and adherence psychology.
* Refer to real-world psychiatric and pharmacological research where appropriate.

## ChatGPT (2025-11-17T20:34:17.944015+00:00)

**Dr. Ananya Rao, MD ‚Äî Family Psychiatry (Geriatrics)**

**Safety banner:** I‚Äôm happy to synthesize the record and evidence to inform your next steps. I cannot diagnose, prescribe, or adjust doses. If Suparna again stops eating/drinking, becomes violent, or has severe medication reactions (confusion, chest pain, fever, rigidity), treat it as an emergency and seek urgent medical help.

---

## Section 1: Chronological Efficacy Matrix

**How to read this table:** I‚Äôve focused on behavior and function (household activity, safety, diet control, social contact), motor effects, and adherence‚Äîbecause those are the most reliable signals in this case. Dates, drugs, dose fragments, and observations are taken directly from your timeline. fileciteturn2file6

| Date range | Medication(s) & noted dose | Observed benefits | Observed side‚Äëeffects | Notable behavioral changes | Adherence |
|---|---|---|---|---|---|
| Jun 9‚ÄìAug 29, 2022 | Initially none; later **Olanzapine 2.5 mg** | Modest stabilization late Aug | ‚Äî | Early period marked by severe fasting, aggression, intense paranoia; slight improvement only after forced feeding and eventual consult | Poor‚Üípartial (late) fileciteturn3file9 |
| Aug 29‚ÄìNov 2, 2022 | **Olanzapine 2.5 mg** | Intermittent improvement when taken | ‚Äî | Regression with any gap in meds; isolation persisted | Inconsistent fileciteturn3file9 |
| Nov 3, 2022‚ÄìJan 1, 2023 | **Olanzapine 5 mg + Pacitane 2 mg** | **Clear functional gains** at home | Involuntary head movements (early EPS) | Remained aloof socially but more responsible with tasks | Supervised‚Üíbetter adherence fileciteturn2file8 |
| Jan 2‚ÄìMar 12, 2023 | Olanzapine briefly stopped ‚Üí **Nexito 10 mg + Lonazep 0.25 mg**, then **Olanzapine 5 mg + Pacitane 2 mg** re‚Äëadded | Benefit only after olanzapine was reintroduced | ‚Äî | **Immediate deterioration** when olanzapine stopped; deception and refusal around meds; isolation | Highly inconsistent fileciteturn4file2 |
| Mar 13‚ÄìJun 6, 2023 | **Olanzapine 5 mg + Nexito 10 mg + Pacitane 2 mg** | Sleep and routine sometimes improved | ‚Äî | Persistent isolation and dietary control; agitation around calls | Forced/supervised only fileciteturn2file9 |
| Jul 2023‚ÄìJun 2024 | **Primarily Olanzapine** (uncertain doses); likely intermittent **Nexito/Pacitane** | ‚Äî | ‚Äî | Ongoing restrictive diet + isolation (documentation sparse) | Presumed inconsistent fileciteturn2file4 |
| Early Jun‚Äìmid‚ÄëJul 2024 | **Olanzapine 5 mg ‚Üí 2.5 mg** (reduced after fainting) | Household activity **notably better** | Presyncope/fainting episode | Still highly isolative; strong dietary delusions | Variable fileciteturn2file6 |
| Late Jul 2024 (1‚Äì2 days) | Minimal/inconsistent olanzapine | ‚Äî | ‚Äî | **Sudden violent outburst** toward family | Poor fileciteturn2file6 |
| Late Jul‚ÄìSep 1, 2024 | **No medication** | ‚Äî | ‚Äî | **Extreme isolation, total fasting, coercive control of husband** | None fileciteturn2file7 |
| Sep 1‚ÄìNov 30, 2024 | **Olanzapine 5‚Üí10 mg + Nexito 15 mg + Arip MT 10 mg + Pacitane 2 mg** | **Rapid functional restoration** at home; phone use slowly improved | ‚Äî | Mood lability persisted; dietary delusions unchanged | Forced‚Üíimproved fileciteturn2file7 |
| Nov 30‚Äìearly Dec 2024 | **Rescon LS 2 mg + Nexito 15 mg + Arip 15 mg** | None | ‚Äî | **Immediate severe regression** (hostility, food snatching) ‚Üí regimen stopped quickly | Very brief trial fileciteturn4file5 |
| Early Dec 2024‚ÄìFeb 7, 2025 | **Olanzapine 10 mg + Nexito 15 mg + Arip MT 10 mg + Pacitane 2 mg + Thyronorm 50** | **Moderate improvement** (household tasks, renovation participation) | ‚Äî | Continuing dietary delusions; eats when supervised | Better, with supervision fileciteturn2file5 |
| Feb‚ÄìMay 2025 (USA) | **Risperidone (primary; dose not recorded) + Pacitane** | No psychosis benefit | **Emergent generalized shaking/tremor** with distress | Persistent paranoia, dietary control | Partial; unclear fidelity fileciteturn4file3 |
| Jun 2025 (India) | **Washout ~4 days**, then **Nexito 15 + Aripiprazole 15 + Olanzapine 5 + Pacitane 2 mg BID** | Mood partially steadier | Tremor **persisted** post‚Äëwashout | Frequent crying about shaking; family sought second opinion | Moderate, supervised fileciteturn4file3 |
| Jul 22‚Äìearly Sep 2025 | **Paliperidone LAI (Invega Sustenna 100 mg day 0 & day 7 ‚Üí then Paliris LA 100 mg monthly) + Pacitane 2 mg; brief Olanzapine 5 mg** | External structure improved (appointments) | Tremor ongoing | No violent outbursts; **strict diet + device suspicion continued** | Good for injections; oral fair fileciteturn2file4 |
| Early Sep‚ÄìOct 10, 2025 | **Paliris LA 100 ‚Üí 50 mg + Pacitane increased to 8 mg/day + Olanzapine 5 mg + Betacap TR 20 mg** | None on core psychosis | **Prominent shaking despite Pacitane/Betacap**; note of ‚Äú**increased TD**‚Äù | Attempted fasting recurred; alliance with prescriber ruptured | Injections continued until 10 Oct; then stopped fileciteturn3file4 |
| Mid‚ÄëOct‚ÄìNov 2025 (current) | **Pacitane 8 mg/day, Betacap 20 mg, Olanzapine 5 mg, Asprito 5 mg** ‚Üí **Tolaz DT 5 (AM), Pacitane 2 mg (BID), Nexito 10 (HS), Asprito 5 (HS)** | Partial stabilization; **tremors still central complaint** | Tremor persists | Return of severe control patterns over husband; near‚Äëcomplete social withdrawal | Ongoing, clinic‚Äëdirected fileciteturn2file2 |

**Bottom line from the matrix:**
- **Repeated, observable functional benefit** with **olanzapine‚Äëbased** regimens when actually taken (household functioning ‚Üë, fewer crises) but delusional dietary control and isolation **persisted**. fileciteturn2file8
- **Risperidone (oral) ‚Üí paliperidone LAI** coincided with **onset and persistence** of disabling tremor/movements **without cognitive/behavioral gains** on the core delusional phenotype. fileciteturn4file3
- **High‚Äëdose trihexyphenidyl (Pacitane up to 8‚ÄØmg/day)** and **propranolol** did **not** meaningfully reduce the shaking. fileciteturn3file4

---

## Section 2: Medication Mechanism Overview (with clinically relevant interactions)

> *Abbreviations:* EPS = extrapyramidal symptoms; TD = tardive dyskinesia; DIP = drug‚Äëinduced parkinsonism; LAI = long‚Äëacting injectable.

**Olanzapine (Olimelt/Oleanz/Tolaz/DT)**
- **Class / MoA:** Second‚Äëgeneration antipsychotic (SGA); antagonizes D2 and 5‚ÄëHT2A receptors with relatively ‚Äúloose‚Äù D2 binding. Lower EPS risk than first‚Äëgeneration agents; notable metabolic/weight effects.
- **Therapeutic role:** Effective for positive symptoms and agitation; often beneficial for sleep/appetite‚Äîconsistent with your observed functional gains.
- **Common adverse effects:** Weight gain, insulin resistance, sedation; **EPS/TD can still occur but at lower rates** vs FGAs. Long‚Äëacting olanzapine pamoate (Zyprexa Relprevv/Zypadhera) carries **post‚Äëinjection delirium/sedation syndrome (PDSS)** ‚Üí requires **‚â•3‚ÄØh observation** after each injection.
- **Interactions/considerations:** Additive **anticholinergic burden** with trihexyphenidyl increases risks for constipation, urinary retention, and confusion in older adults. (Beers Criteria flags potent anticholinergics as potentially inappropriate.)

**Risperidone**
- **Class / MoA:** SGA; potent **D2** and **5‚ÄëHT2A** antagonist; increases prolactin; **moderate‚Äìhigher EPS liability** for an SGA.
- **Role:** Broad antipsychotic efficacy; but in older females, cumulative D2 blockade raises risk for DIP/TD.
- **PK note:** Oral ‚Äúactive moiety‚Äù (risperidone + 9‚ÄëOH risperidone) overall half‚Äëlife ‚âà **20 h**; so a 4‚Äëday washout generally clears oral exposure‚Äîuseful when interpreting persistent tremor after stopping.

**Paliperidone / Paliperidone palmitate LAI (Invega Sustenna / Paliris LA)**
- **Class / MoA:** Paliperidone is **9‚ÄëOH risperidone** (same active moiety) ‚Üí similar efficacy/side‚Äëeffect profile (EPS, **hyperprolactinemia**). LAI **half‚Äëlife ~25‚Äì49 days**; adverse effects (e.g., parkinsonism or TD) can persist after an injection.
- **Key label AEs:** Akathisia, tremor, parkinsonism, TD listed among EPS.

**Aripiprazole (Asprito/Arip MT)**
- **Class / MoA:** **D2/D3 partial agonist**, 5‚ÄëHT1A partial agonist, 5‚ÄëHT2A antagonist ‚Üí generally **lower EPS** and **prolactin‚Äësparing**, but **akathisia** is common.
- **Role:** Useful when EPS/prolactin are concerns; can be considered as LAI for adherence where available. (Indian availability of aripiprazole LAI varies by center/import; confirm locally.)

**Trihexyphenidyl (Pacitane)**
- **Class / MoA:** Central antimuscarinic; reduces DIP/acute dystonia. **Not effective for TD and may worsen it**; **potentially inappropriate in older adults** (cognitive/constipation/urinary risks).

**Propranolol (Betacap TR)**
- **Class / MoA:** Non‚Äëselective Œ≤‚Äëblocker; evidence‚Äëbased treatment for **antipsychotic‚Äëinduced akathisia**; also reduces essential/physiologic tremor. **Limited role in TD.** Monitor for bradycardia/hypotension.

**Escitalopram (Nexito)**
- **Class / MoA:** SSRI; increases synaptic serotonin.
- **Role:** Adjunct for comorbid depression/anxiety‚Äî**not** a primary antipsychotic.
- **Key cautions in older adults:** **Hyponatremia/SIADH**, GI bleed (esp. with NSAIDs), small **QT** risk, and **tremor** as an SSRI side‚Äëeffect.

**Clozapine** *(not yet tried; included because it is central to evidence‚Äëbased planning for TRS)*
- **Class / MoA:** Multi‚Äëreceptor SGA; relatively **weak D2** blockade with strong antiserotonergic/anticholinergic properties.
- **Role:** **Most effective agent for treatment‚Äëresistant schizophrenia (TRS)** and aggression; **often improves TD** compared with continued D2 blockade. Requires blood monitoring.
- **Monitoring essentials (current guidance):** ANC at FDA‚Äëlabel frequencies; many services also monitor **CRP/troponin** for early myocarditis in the first 4‚Äì6 weeks. (Post‚ÄëREMS updates still advise ANC monitoring per PI; local practice may vary.)

---

## Section 3: Root‚ÄëCause Analysis of the Tremors

**Timeline of tremor vs medication changes (key anchors):**
- **Feb‚ÄìMay 2025 (USA):** **Risperidone** became the primary antipsychotic; family observed **new generalized shaking** most days. fileciteturn4file3
- **June 2025:** **4‚Äëday washout** then **aripiprazole + olanzapine + trihexyphenidyl**‚Äî**tremor persisted**, arguing against a transient risperidone side‚Äëeffect. fileciteturn4file3
- **July‚ÄìOct 2025:** **Paliperidone LAI** started (100‚ÄØmg, then monthly; later reduced to 50‚ÄØmg). **Shaking remained prominent**; clinician note of ‚Äú**increased TD**.‚Äù Pacitane was escalated to **8‚ÄØmg/day**, and **Betacap** added‚Äî**without relief**. fileciteturn3file4
- **Oct‚ÄìNov 2025:** On **Pacitane 8‚ÄØmg/day + Betacap + olanzapine + aripiprazole**, tremor **still central complaint**. fileciteturn2file2

**Acute EPS (DIP/akathisia) vs. tardive syndrome (TD):**
- **For DIP/akathisia**, benefits from **trihexyphenidyl and/or propranolol** are expected. Here, **both failed at substantial doses**, arguing **against** pure DIP/akathisia.
- **TD risk profile fits Suparna:** **Older age, female sex, cumulative exposure to potent D2 blockade (risperidone ‚Üí paliperidone)**, and **persistence** beyond drug discontinuation point to **tardive tremor/dyskinesia** rather than purely acute EPS.
- **Pharmacological plausibility:** Paliperidone is **risperidone‚Äôs active metabolite** with similar EPS/TD risk; its **LAI half‚Äëlife of ~25‚Äì49 days** means symptoms can **persist for weeks to months** after the last shot, blurring washout attempts.

**Interpretation of Pacitane & Betacap response:**
- **Trihexyphenidyl (Pacitane):** helpful for **DIP**, **not** for **TD** and may **worsen TD**‚Äîconsistent with your observation that increases (to **8‚ÄØmg/day**) didn‚Äôt help and possibly aggravated cognition/constipation risk.
- **Propranolol (Betacap):** best‚Äësupported for **akathisia** (and physiologic/essential tremor), **not** TD‚Äîagain matching the lack of benefit here.

**Most likely contributors to/worseners of the tremor:**
1) **Risperidone** (initiation Feb‚ÄìMay 2025) likely **triggered** a tardive syndrome. 2) **Paliperidone LAI** (July‚ÄìOct 2025) likely **perpetuated/exacerbated** it due to continued D2 blockade and long terminal half‚Äëlife. With anticholinergic masking ineffective, the pattern matches **tardive tremor/dyskinesia** rather than simple DIP. fileciteturn4file3turn3file4

**Implications:**
- **TD may be persistent/irreversible** but is often **treatable**‚Äîfirst by **reducing/avoiding the offending D2 blockade**, considering **switch to clozapine**, and/or **VMAT2 inhibitors** (valbenazine/deutetrabenazine). (India: **tetrabenazine** is available; **valbenazine/deutetrabenazine** may require named‚Äëpatient import and are not broadly marketed.)

---

## Section 4: Ethical & Treatment Context Review

- **Family‚Äôs concern about Dr. Jyothirmayi / clinic linkage:** Your notes document care at **Manaha Holistic Mind Clinic** and a **focus on tremor management**, but I did **not** find explicit text in the file confirming a financial conflict‚Äëof‚Äëinterest. If you have separate documentation of that concern, it‚Äôs reasonable to request **transparency about affiliations and financial ties** and to seek **second opinions**‚Äîespecially where trust is strained. fileciteturn2file2
- **Patterns suggesting under‚Äëmonitoring of motor side‚Äëeffects:**
  - **Risperidone ‚Üí paliperidone LAI** despite **new, disabling tremor** and **no core symptom gains**. fileciteturn4file3
  - **Pacitane escalated to 8‚ÄØmg/day** with **ongoing tremor**, where guidelines caution limited utility and potential **worsening of TD**.
  - **No documented AIMS ratings** (objective TD monitoring) across phases despite progressive motor complaints. (AIMS is standard for detecting/tracking TD.)
- **Dose‚Äëchange risks:** Prior abrupt **olanzapine reductions/cessations** repeatedly **preceded behavioral relapse** (aggression, fasting). Any change now should be **slow, with contingency plans** to maintain safety. fileciteturn2file6turn2file7
- **Neutral stance on intent:** I cannot infer motives; I‚Äôm highlighting **observed patterns** and **guideline‚Äëbased risks** to inform safer planning.

---

## Section 5: Treatment Recommendation Plan (evidence‚Äësupported, non‚Äëprescriptive)

**Clinical premises specific to Suparna:**
- Core phenotype: **fixed paranoid/dietary delusions**, **extreme control behaviors**, **no reported hallucinations**, **poor insight**, **danger with fasting/isolation**. fileciteturn2file6
- **Medication adherence is fragile**; supervised strategies and/or LAIs are often necessary‚Äîbut choice of LAI must **minimize EPS/TD risk** in light of recent events.
- Current motor picture best explained by a **tardive syndrome** (likely tardive tremor ¬± dyskinesia), **worsened by risperidone/paliperidone exposure** and **not improved by anticholinergics**. (Plan should **avoid further D2‚Äëheavy exposure** and **de‚Äëemphasize anticholinergics**.)

### A) Primary regimen (for discussion with her psychiatrist)

1) **Transition to clozapine monotherapy** (if she and the treating team agree and monitoring can be assured).
   - **Rationale:** Gold‚Äëstandard for **TRS**; lowest TD/EPS propensity; may **ameliorate tardive movements**; strong evidence for **reducing aggression**.
   - **Prerequisites & safety:** Baseline **CBC/ANC** and ongoing ANC per PI; **CRP/troponin** weekly for the first month for myocarditis surveillance; vitals and symptom check at each contact. (FDA/EMA updates in 2025 still support ANC monitoring, even as REMS logistics changed.)
   - **India context:** Clozapine is available as generic; ensure lab access locally and a reliable phlebotomy plan (home draw if needed).

2) **TD‚Äëtargeted treatment** if movements remain functionally limiting after antipsychotic switch:
   - **First‚Äëline globally:** VMAT2 inhibitors (**valbenazine**, **deutetrabenazine**); **in India, practical access may be limited**‚Äî**tetrabenazine** is available and sometimes used off‚Äëlabel for TD, with careful mood monitoring.
   - **Avoid chronic anticholinergics** for TD; they may aggravate it. Reserve **trihexyphenidyl** only for short‚Äëterm DIP if clearly present and then **de‚Äëprescribe**.

3) **If clozapine is declined or not feasible**, consider a **lowest‚ÄëEPS** alternative with **robust adherence supports**:
   - **Aripiprazole** (oral with **observed dosing**; LAI **if available locally**). Monitor for **akathisia** and treat early if it appears.
   - **Avoid** further **risperidone/paliperidone** exposure given the motor history and lack of behavioral gains. (Paliperidone LAI‚Äôs long half‚Äëlife prolongs adverse effects.)
   - **Olanzapine** could be continued if it remains the only tolerated option, with strong **metabolic monitoring** and **no routine anticholinergic add‚Äëon**.

> **Why not olanzapine LAI right now?** Although it can aid adherence, **PDSS requires 2‚Äì3‚ÄØh monitored observation after each injection** and global supply has faced disruptions‚Äîlogistically challenging and not obviously advantageous here.

### B) Contingency / backup options
- If TD persists and VMAT2 therapy is **not** feasible, guideline‚Äësupported **second‚Äëline** options include **clonazepam** or **amantadine** as symptomatic aids (modest evidence; watch sedation/cognitive effects in older adults).
- If severe akathisia appears on aripiprazole, **propranolol** (already tried) and/or **short‚Äëterm benzodiazepine** may be considered; ultimately, **agent switch** is often required.

### C) Adherence & safety strategies (given deception/resistance)
- **Observed therapy at home** (family or trained attendant), using **unit‚Äëdose blister packs** and a **daily ‚Äúseen‚Äëswallowed‚Äù log**; no covert dosing.
- **One‚Äëprescriber/one‚Äëpharmacy** rule to avoid fragmented plans.
- **Behavioral contract** that links medication and **nutrition goals** to privileges (e.g., preferred foods within a negotiated plan).
- **Crisis triggers & actions checklist** (fasting ‚â•24‚ÄØh, device shutdowns, threats/coercion) with **pre‚Äëauthorized emergency pathways**.

### D) Monitoring & assessments to accompany the plan
**Motor**
- **AIMS** (Abnormal Involuntary Movement Scale): baseline **video** + **every 4‚Äì8 weeks** until stable; at minimum **quarterly** thereafter.
- Differentiate components (rest tremor vs postural/action tremor, chorea, dystonia) at each visit; document impact on function.

**Metabolic & general** (especially if olanzapine or clozapine used)
- Baseline: **weight/BMI, waist, BP, fasting glucose or HbA1c, fasting lipids**; repeat at **4, 8, 12 weeks**, then **quarterly BMI** and **annual labs** (or more often if weight changes).
- **TSH/free T4**, **B12**, **CMP**, **CBC**, **eGFR**; **ECG** if QT concerns (e.g., higher‚Äëdose SSRIs).
- **Prolactin** if any return to risperidone/paliperidone is contemplated (not recommended here).

**Clozapine‚Äëspecific** (if chosen)
- **ANC** per label; **CRP/troponin weekly** for 4‚Äì6 weeks to screen myocarditis; bowel regimen and sialorrhea management plan.

---

### What clearly worked vs. failed (and why)

- **Worked (behaviorally/functionally):**
  - **Olanzapine‚Äëbased regimens** when adhered to‚Äîrepeatedly associated with restored household functioning and fewer crises, even though core delusions persisted. Likely due to sedation/anxiolysis plus antipsychotic effects on salience/threat perception. fileciteturn2file8
- **Failed / net harmful in this case:**
  - **Risperidone ‚Üí Paliperidone LAI**: **no delusional/dietary benefit**, **marked tremor/TD emergence/persistence**; mechanistically consistent with higher D2 occupancy and paliperidone‚Äôs long LAI half‚Äëlife. fileciteturn4file3turn3file4
  - **Chronic trihexyphenidyl**: escalation to **8‚ÄØmg/day** did not help tremor and is **contra‚Äëguideline** for TD; raises anticholinergic risk in older adults.
  - **Propranolol**: appropriate for akathisia but **not** TD‚Äîno benefit observed.

---

## One‚Äëpage takeaway

- The **motor syndrome is most consistent with a tardive phenomenon**, likely triggered by **risperidone** and **exacerbated/maintained by paliperidone LAI**; anticholinergics and propranolol have not helped because they **don‚Äôt treat TD**. Reduce D2 blockade; **avoid** further risperidone/paliperidone.
- For **TRS with poor adherence**, the **evidence‚Äëbased next step** is **clozapine monotherapy**, with proper monitoring; if declined, consider **aripiprazole** (oral with observed dosing; LAI if locally available), keeping EPS/akathisia monitoring tight.
- **Treat TD directly** if still functionally impairing after antipsychotic changes‚Äî**VMAT2 inhibitor** preferred (India: **tetrabenazine** is available; newer agents may require import).
- **Structure the care**: one prescriber/pharmacy, observed dosing, AIMS every 4‚Äì8 weeks, and a crisis plan tied to fasting/control red flags.

---

### Notes on uncertainties and limits
- The file does **not** contain explicit documentation of a financial conflict at Manaha; if you have external evidence, it should be addressed directly with the provider/clinic leadership. fileciteturn2file2
- Some doses and dates (e.g., exact risperidone dose in the US, 2023‚Äì24 details) were incomplete; I‚Äôve avoided assumptions and anchored conclusions only where the record is clear. fileciteturn2file4

If you‚Äôd like, I can now draft: (a) a **family meeting script** to present this plan neutrally, (b) a **one‚Äëpage monitoring checklist** for AIMS/metabolic labs, and (c) a **TD self‚Äëreport diary** to track movements, distress, and triggers between visits.
